DUBLIN–(BUSINESS WIRE)–The “2019
Predictions of the Global Life Sciences Industry” report has
been added to ResearchAndMarkets.com’s offering.
The global life science industry is in a state of flux. While the recent
years have seen the advent of multiple novel technologies, such as
in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and
liquid biopsy, the industry stands at a crossroad with challenges in
scaling-up and commercializing such technologies. In addition, companies
are also striving to customize and expand the application of existing
technologies into emerging areas, such as Femtech and emerging
geographies such as Asia-Pacific.
As the life sciences industry attempts to catch up with the digital
revolution, the movement towards customer centricity is challenging
traditional stakeholders such as Big Pharma, diagnostic companies, and
site management organizations (SMOs) to improve their business strategy
and embrace mHealth solutions. Companies in the life sciences industry
are increasingly adopting a digital-first mindset in the wake of rapidly
declining returns on research and development (R&D) and the complexity
of financial precision medicine equation catering to select and small
population groups.
The future will bring more digitally integrated solutions based on R&D
advancements; this will influence how clinical trials are designed and
how new products are commercialized. While the need for value-based-care
grows along with strained profitability, Big Pharma needs to
decentralize and outsource manufacturing of novel cell and gene
therapies to contract development and manufacturing organization (CDMOs).
The convergence of pharmaceuticals, clinical laboratory testing
services, and companion diagnostics, which has been enabled by digital
connectivity, is driving regulatory and commercial changes in the global
life sciences industry. Mergers and acquisitions (M&As) play a very
significant role in achieving these industry changes.
Although companies have relied on M&As in the past to fill gaps in their
portfolios, they are now recalibrating their focus to experience
synergies and radical growth; companies are also increasingly relying on
assets from the Startup 2.0 ecosystem. The global life sciences industry
has been adopting path-breaking life science technologies, which are
helping to make precision healthcare a reality. This research service
focuses on the critical issue of monetization in value-based care in the
life sciences industry.
Key Issues Addressed
-
What are the key factors that will influence the size and direction of
the global life sciences industry in 2019? -
What technology developments in the global life sciences industry in
2018 will have an impact during 2019? -
What are the key opportunities and strategic imperatives for companies
in 2019? -
What are the innovative monetization models used by companies looking
to commercialize and distribute novel solutions?
Key Topics Covered:
1. Executive Summary
- Scope and Segmentation
- Key Questions This Study Will Answer
- Life Sciences – Segment Snapshot
- Big Market Themes
2. Life Sciences – Predictions for 2019
-
Prediction 1: Demonstrated Benefits of Virtual Clinical Trials to
Increasingly Challenge Traditional SMO/PRO Vendors - Prediction 1: Key Companies to Watch
-
Prediction 2: Single-use Technology to Enable Decentralization of
Manufacturing of Cell and Gene Therapy Products - Prediction 2: Key Companies to Watch
-
Prediction 3: Amalgamation of Online and Offline Distribution Channels
to Drive Growth in the DTCGT Market - Prediction 3: Key Companies to Watch
-
Prediction 4: Application of Liquid Biopsy for Clinical Trial Patient
Selection and Early Cancer Screening to Drive Growth - Prediction 4: Key Companies to Watch
-
Prediction 5: Rising Number of IVF Cases in APAC and Adoption of PGD
Tests to Extend Service Reach to a Wider Audience - Prediction 5: Key Companies to Watch
3. Key Conclusions
- Strategic Imperatives for Life Sciences
- Legal Disclaimer
4. Appendix
For more information about this report visit https://www.researchandmarkets.com/research/q56vfr/2019_predictions?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology